Placebo News and Research

RSS

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Virtual reality and music may help lower blood pressure during emergencies

A virtual reality landscape of a flowing river and trees, accompanied by classical music, can help to reduce patients' blood pressure significantly within 15 minutes of their being seen in an emergency department.

25 Sep 2026

Common anti-epileptic medication shows promise in reducing migraine aura

A new study by researchers at Lund University in Sweden found that 85 percent of patients with aura-dominant migraine experienced a reduction in monthly aura days by at least half following treatment with the anti-epileptic drug lamotrigine.

25 Sep 2026

The heart effects of antidepressants may depend as much on the patient as the drug

Antidepressants differed in their effects on QTc, with amitriptyline and escitalopram producing small average increases, and the magnitude of changes varying according to individual patient characteristics. The trials did not detect an increase in early major cardiovascular events or non-suicidal sudden death, but they were not large or long enough to rule out rare or later cardiovascular events.

24 Sep 2026

Beetroot juice may make swimming feel easier without making swimmers faster

A systematic review and meta-analysis of 12 studies, with nine contributing data from 120 swimmers, found no significant improvement in swimming time-trial performance or post-exercise blood lactate with beetroot juice or dietary nitrate supplementation. Supplementation produced a small reduction in perceived exertion, but the effect varied across studies, and the certainty of evidence for swimming performance was low.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

WSU study reveals acute effects of cannabis on physiological stress-related outcomes

Cannabis is often used as a stress reliever, but a new study suggests that some of the body's stress response systems don't get the message.

23 Sep 2026

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off.

21 Sep 2026

Daily vitamin C may benefit pre-cancerous blood disorder patients

Vitamin C is an essential nutrient that supports immune function, promotes wound healing and protects cells from molecular damage.

21 Sep 2026

Antibody therapy teaches the immune system to control HIV

There is no cure for HIV. While scientists have made considerable progress in controlling the infection, patients still must take daily antiretroviral medication for the rest of their lives.

18 Sep 2026

Experts call for eating-disorder screening before GLP-1 treatment

An international multidisciplinary panel developed consensus-based recommendations for GLP-1 receptor agonist use in people with eating disorders, calling for screening, individualized monitoring, patient education, and further research into safety and potential therapeutic effects. The experts cautioned that current evidence remains limited and inconsistent, particularly outside binge eating disorder, and identified major gaps in understanding the risk of new or recurrent eating disorders during treatment.

16 Sep 2026

Shatavari may affect more than hormones, and the gut could help explain why

A review in Nutrients examined how bioactive compounds in Asparagus racemosus (Shatavari) may influence cognitive health through the microbiota-gut-brain axis, estrogen-related signaling, neuroinflammation, oxidative stress, and neurotransmitter regulation. Evidence from computational, cellular, animal, and limited human studies suggests several plausible biological pathways, but key questions remain about bioavailability, brain exposure, dosing, and clinical efficacy.

16 Sep 2026

UCSF researchers urge more convincing placebos in psychedelic trials

UC San Francisco researchers are weighing in on one of the biggest challenges in psychedelic science, arguing that clinical trials need more convincing placebo treatments to better measure the drugs' true effects.

16 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026